TY - JOUR

T1 - Increased myeloid-derived suppressor cell activation in clonal cytopenia of undetermined significance and low-risk myelodysplastic syndrome

AU - Bentivegna, Sofia

AU - Côme, Christophe

AU - Porse, Bo

AU - Andersen, Mads Hald

AU - Grønbæk, Kirsten

N1 - Funding Information: This project has received funding from the European Union\u2019s Horizon 2020 research and innovation programme under the Marie Sk\u0142odowska\u2010Curie grant agreement No 801481, the Greater Copenhagen Health Science Partners (Clinical Academic Group in Translational Hematology), and a centre grant from the Novo Nordisk Foundation (Novo Nordisk Foundation Center for Stem Cell Biology, DanStem; grant NNF17CC0027852). This project is also part of the Danish Research Center for Precision Medicine in Blood Cancers (Danish Cancer Society grant R223\u2010A13071).

PY - 2024

Y1 - 2024

N2 - Clonal cytopenia of undetermined significance (CCUS) is a condition characterized by the presence of persistent cytopenia in one or more blood cell lineages, accompanied by the detection of one or more somatic mutations associated with myeloid neoplasms in haematopoietic cells, with a variant allele frequency (VAF) of 2% or higher.1, 2 Patients with CCUS have an increased risk of developing myelodysplastic syndrome (MDS) or acute myeloid leukaemia. Numerous factors increase the risk of progression, including the VAF, the number and type of mutations.3-5 Several studies have highlighted molecular and clinical similarities between CCUS and low-risk MDS (LR-MDS) patients,6, 7 suggesting that CCUS represents an early manifestation of LR-MDS and underlining a biological continuum between these entities.

AB - Clonal cytopenia of undetermined significance (CCUS) is a condition characterized by the presence of persistent cytopenia in one or more blood cell lineages, accompanied by the detection of one or more somatic mutations associated with myeloid neoplasms in haematopoietic cells, with a variant allele frequency (VAF) of 2% or higher.1, 2 Patients with CCUS have an increased risk of developing myelodysplastic syndrome (MDS) or acute myeloid leukaemia. Numerous factors increase the risk of progression, including the VAF, the number and type of mutations.3-5 Several studies have highlighted molecular and clinical similarities between CCUS and low-risk MDS (LR-MDS) patients,6, 7 suggesting that CCUS represents an early manifestation of LR-MDS and underlining a biological continuum between these entities.

U2 - 10.1111/bjh.19609

DO - 10.1111/bjh.19609

M3 - Letter

AN - SCOPUS:85196558001

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

ER -